Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Kindred Biosciences (KIN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 443,456
  • Shares Outstanding, K 33,800
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,880 K
  • 36-Month Beta 0.33
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.40
  • Number of Estimates 2
  • High Estimate -0.38
  • Low Estimate -0.42
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -37.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.46 +14.31%
on 10/12/18
14.05 -6.76%
on 10/01/18
-0.25 (-1.87%)
since 09/17/18
3-Month
11.46 +14.31%
on 10/12/18
15.75 -16.83%
on 08/13/18
+0.55 (+4.38%)
since 07/17/18
52-Week
6.80 +92.65%
on 11/01/17
15.75 -16.83%
on 08/13/18
+4.95 (+60.74%)
since 10/17/17

Most Recent Stories

More News
Kindred Biosciences to Present at Cantor Global Healthcare Conference and Ladenburg Thalmann 2018 Healthcare Conference

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Cantor Global Healthcare Conference on October...

KIN : 13.10 (-0.15%)
Kindred Biosciences to Participate in the CL King 16th Annual Best Ideas Conference, Lake Street Capital Markets 2nd Annual Best Ideas Growth Conference and LD Micro San Francisco Summit

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the LD Micro San Francisco Summit taking place...

KIN : 13.10 (-0.15%)
Kindred Biosciences to Participate in the B. Riley FBR Annual Healthcare Conference

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the B. Riley FBR Annual Healthcare Conference...

KIN : 13.10 (-0.15%)
Kindred Bio: 2Q Earnings Snapshot

BURLINGAME, Calif. (AP) _ Kindred Biosciences Inc. (KIN) on Thursday reported a loss of $11.2 million in its second quarter.

KIN : 13.10 (-0.15%)
Kindred Biosciences Announces Second Quarter 2018 Financial Results

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June...

KIN : 13.10 (-0.15%)
Kindred Biosciences to Announce Second Quarter 2018 Financial Results

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its second quarter 2018 financial...

KIN : 13.10 (-0.15%)
Kindred Biosciences Announces Commercial Availability of Mirataz® (mirtazapine transdermal ointment) to Veterinarians in the United States

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that Mirataz® (mirtazapine transdermal ointment)...

KIN : 13.10 (-0.15%)
Kindred Bio: 1Q Earnings Snapshot

BURLINGAME, Calif. (AP) _ Kindred Biosciences Inc. (KIN) on Tuesday reported a loss of $10 million in its first quarter.

KIN : 13.10 (-0.15%)
Kindred Biosciences Announces First Quarter 2018 Financial Results

Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March...

KIN : 13.10 (-0.15%)
Kindred Biosciences Receives FDA Approval of Mirataz(TM) (mirtazapine transdermal ointment) for the Management of Weight Loss in Cats

Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the U.S. Food and Drug Administration's Center for Veterinary...

KIN : 13.10 (-0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade KIN with:

Business Summary

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have...

See More

Key Turning Points

2nd Resistance Point 13.52
1st Resistance Point 13.31
Last Price 13.10
1st Support Level 12.75
2nd Support Level 12.39

See More

52-Week High 15.75
Last Price 13.10
Fibonacci 61.8% 12.33
Fibonacci 50% 11.27
Fibonacci 38.2% 10.22
52-Week Low 6.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar